Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report

INTRODUCTION: Papillary renal cell carcinoma (PRCC), which represents around 20% of renal cell carcinomas, is a heterogeneous disease that includes different tumor types with several clinical and molecular phenotypes. Nivolumab, a fully human IgG4 programed cell death protein 1 immune checkpoint inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Bañobre, Juan, Anido, Urbano, Abdulkader, Ihab, Antúnez-López, José, López-López, Rafael, García-González, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118772/
https://www.ncbi.nlm.nih.gov/pubmed/27921007
http://dx.doi.org/10.3389/fonc.2016.00250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118772/
https://www.ncbi.nlm.nih.gov/pubmed/27921007
http://dx.doi.org/10.3389/fonc.2016.00250

Ejemplares similares